このエントリーをはてなブックマークに追加
ID 31183
file
creator
Ochiai, Mariko
Takasugi, Norihisa
Kiribayashi, Kei
Kawai, Toru
Usui, Koji
Shigemoto, Kenichiro
Hamaguchi, Naoki
Yorioka, Noriaki
subject
Vitamin K2
Bone metabolism markers
Intact parathyroid hormone
Hemodialysis
NDC
Medical sciences
abstract
Background: A low level of intact parathyroid hormone (PTH) is an indicator of adynamic bone disease in hemodialysis patients, and is associated with a significant increase of all-cause mortality. Thus, effective treatment for adynamic bone disease is required. We previously investigated the effect of vitamin K2 on adynamic bone disease. In this study, we assessed the efficacy of oral vitamin K2 in a controlled trial.

Methods: Forty hemodialysis patients with low intact PTH levels (<100 pg/ml) were randomly divided into two groups, which were a vitamin K2 group receiving oral menatetrenone (45 mg/day) for 1 year and a control group without vitamin K2. Venous blood samples were collected at baseline and during the study for measurement of bone metabolism parameters.

Results: Thirty-three patients completed follow-up. There was a significant increase of the serum intact osteocalcin level after 1 month of vitamin K2 administration. Serum levels of intact PTH, bone alkaline phosphatase, and cross-linked N-terminal telopeptide of type I collagen increased significantly after 12 months in the vitamin K2 group. The serum osteoprotegerin level was decreased after 12 months in the vitamin K2 group, but the change was not significant.

Conclusion: Vitamin K2 therapy improves bone remodeling in hemodialysis patients with a low intact PTH level.
journal title
Nephron Clinical Practice
volume
Volume 117
issue
Issue 1
start page
c15
end page
c19
date of issued
2011
publisher
Karger
issn
1660-2110
publisher doi
language
eng
nii type
Journal Article
HU type
Journal Articles
DCMI type
text
format
application/pdf
text version
author
rights
Copyright (c) 2010 S. Karger AG, Basel
relation url
department
Graduate School of Biomedical Science